Atherogenesis is a complex process influenced by numerous
|
|
- Barnard McDowell
- 5 years ago
- Views:
Transcription
1 Peroxisome Proliferator-Activated Receptor Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease David M. Flavell, PhD; Yalda Jamshidi, PhD; Emma Hawe, MSc; Inés Pineda Torra, PhD; Marja-Riitta Taskinen, MD; M. Heikki Frick, MD; Markku S. Nieminen, MD; Y. Antero Kesäniemi, MD; Amos Pasternack, MD; Bart Staels, PhD; George Miller, MD; Steve E. Humphries, PhD, FRCPath, MRCP; Philippa J. Talmud, PhD, DSc, FRCPath; Mikko Syvänne, MD Background Peroxisome proliferator-activated receptor (PPAR ) regulates the expression of genes involved in lipid metabolism and inflammation, making it a candidate gene for atherosclerosis and ischemic heart disease (IHD). Methods and Results We investigated the association between the leucine 162 to valine (L162V) polymorphism and a G to C transversion in intron 7 of the PPAR gene and progression of atherosclerosis in the Lopid Coronary Angiography Trial (LOCAT), a trial examining the effect of gemfibrozil treatment on progression of atherosclerosis after bypass surgery and on risk of IHD in the second Northwick Park Heart Study (NPHS2), a prospective study of healthy middle-aged men in the United Kingdom. There was no association with plasma lipid concentrations in either study. Both polymorphisms influenced progression of atherosclerosis and risk of IHD. V162 allele carriers had less progression of diffuse atherosclerosis than did L162 allele homozygotes with a similar trend for focal atherosclerosis. Intron 7 C allele carriers had greater progression of atherosclerosis than did G allele homozygotes. The V162 allele attenuated the proatherosclerotic effect of the intron 7 C allele. Homozygotes for the intron 7 C allele had increased risk of IHD, an effect modulated by the L162V polymorphism Conclusions The PPAR gene affects progression of atherosclerosis and risk of IHD. Absence of association with plasma lipid concentrations suggests that PPAR affects atherosclerotic progression directly in the vessel wall. (Circulation. 2002;105: ) Key Words: atherosclerosis genetics coronary disease Atherogenesis is a complex process influenced by numerous factors, including dyslipidemia, endothelial dysfunction, oxidative stress, and inflammation, and involves the interaction of monocyte/macrophages, endothelial cells, and smooth muscle cells. 1 Peroxisome proliferator-activated receptor (PPAR ) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. 2 Ligands for PPAR include fatty acids, eicosanoids, and the fibrate class of hypolipidemic drugs. 3 PPAR regulates the expression of genes involved in lipid metabolism, and fibrate treatment causes a dramatic decrease in triglycerides, a lesser decrease in LDL cholesterol, and an increase in HDL cholesterol, producing a less atherogenic lipid phenotype. 4 PPAR is expressed at high levels in liver, heart, skeletal muscle, and kidney, 5 tissues that catabolize fatty acids. PPAR also regulates proatherosclerotic processes in the vessel wall. PPAR is expressed in endothelial cells 6 and smooth muscle cells 7 and in monocyte/macrophages in the circulation 8 and in atherosclerotic plaques. 9 In these cell types, PPAR regulates the expression of genes influencing monocyte recruitment (monocyte chemotactic protein-1, 10 endothelin 11 ), adhesion (vascular cell adhesion model-1 [VCAM-1] 12,13 ) and transmigration (matrix metalloproteinase-9 [MMP-9] 14 ), foam cell formation (SR-BI 9 ), reverse cholesterol transport (liver X receptor [LXR ], ATP binding cassette transporter 1 [ABCA1] 15 ), and thrombogenicity (tissue factor 16,17 ). PPAR also may influence atherosclerosis through antiinflammatory properties. PPAR inhibits the activator protein (AP-1) 11,18 and nuclear factor- B 7,11,18,19 inflammatory cytokine signaling pathways. Fenofibrate lowers plasma concentrations of proinflammatory cytokines. 7,20 PPAR knockout Received November 20, 2001; revision received January 18, 2002; accepted January 18, From the Centre for Cardiovascular Genetics, Department of Medicine, Royal Free and University College of London Medical School, London, UK (D.M.F., Y.J., E.H., S.E.H., P.J.T.); U.325 INSERM, Département d Athérosclérose, Institut Pasteur, Lille, France (I.P.T., B.S.); the Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (M.-R.T., M.H.F., M.S.N., M.S.); the Department of Medicine, University of Oulu, Oulu, Finland (Y.A.K.); the Department of Medicine, Tampere University Hospital, Tampere, Finland (A.P.); and Medical Research Council Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, The Medical College of St Bartholomew s Hospital, London, UK (G.M.). Correspondence to David M. Flavell, Centre for Cardiovascular Genetics, Department of Medicine, Royal Free and University College of London Medical School, Rayne Building, 5 University St, London WC1E 6JJ, UK. d.flavell@ucl.ac.uk 2002 American Heart Association, Inc. Circulation is available at DOI: /01.CIR
2 Flavell et al PPAR Gene Variants and Heart Disease 1441 TABLE 1. Baseline Characteristics of Subjects in LOCAT and NPHS2 LOCAT (n 297) Controls (n 2560) NPHS2 Cases (n 176) Age, y BMI, kg/m Smokers, % Systolic blood pressure, mm Hg Cholesterol, mmol/l Triglycerides, mmol/l Fibrinogen, g/l N/A LOCAT data are for the 297 subjects with both genotype data available. Data are mean SD. mice have a greater 18,21 inflammatory response. Oxidative stress also influences atherosclerosis. 22 PPAR activators reduce oxidative stress, 23 and PPAR knockout mice have higher levels of proinflammatory cytokines and lipid peroxides. 19 Fibrates reduced the progression of coronary atherosclerosis in the Bezafibrate Coronary Atherosclerosis Trial (BECAIT) and the Lopid Coronary Angiography Trial (LOCAT) and reduced the incidence of coronary artery disease in the Helsinki Heart Study and Veterans Administration HDL-cholesterol Intervention Trial (VA-HIT). 24 Thus, PPAR is expressed in cell types involved in atherosclerosis, and PPAR activators have pleiotropic beneficial effects on proatherosclerotic factors. To investigate the role of PPAR in human atherosclerosis, we examined the association between two polymorphisms in the PPAR gene, the functional leucine 162 to valine (L162V) variant 25,26 and a novel polymorphism in intron 7, and progression of atherosclerosis in LOCAT, a trial examining the effect of gemfibrozil treatment on progression of atherosclerosis in Finnish patients with CABG and low HDL 27 and in the second Northwick Park Heart Study (NPHS2), a prospective study examining the risk of heart disease in healthy middle-aged men in the United Kingdom. 28 Methods Study Samples A cohort of 395 Finnish men 70 years old with HDL cholesterol 1.1 mmol/l, LDL cholesterol 4.5 mmol/l, and triglycerides 4.0 mmol/l entered the study (baseline characteristics are shown in Table 1). Current smokers and subjects with severe hypertension, obesity, history of diabetes, or fasting glucose concentration 7.8 mmol/l were excluded. Patients had undergone coronary artery bypass surgery and were treated with placebo or gemfibrozil (1200 mg/d) (Parke Davis) for 2.5 years. 27 Coronary angiography was performed at baseline and on average at 32 months after therapy commencement. Cholesterol and triglyceride concentrations were determined in LDL and HDL subfractions. 29 Angiographic images were analyzed with a computer-assisted quantitative method. 30 Diffuse atherosclerosis is defined as a change in average diameter of coronary segments ( ADS) from baseline to follow-up angiogram. Focal atherosclerosis is a change in minimum luminal diameter ( MLD) of stenoses. Of subjects with L162V genotype, 302 had ADS data and 297 subjects had MLD data. For those with intron 7 genotype, 283 had ADS and 278 had MLD data. The Second Northwick Park Heart Study (NPHS2) is a prospective study of ischemic heart disease (IHD) in 3012 middle-aged (50 to 61 years) healthy men in the United Kingdom over a period of 7 years (see Table 1 for baseline characteristics). Exclusion criteria included history of type 2 diabetes, unstable angina, or previous myocardial infarction or stroke. 28 Plasma concentrations of cholesterol, HDL cholesterol, triglycerides, apolipoprotein (apo)ai, and apob were determined. Ischemic events is a measure of acute myocardial infarction (n 136), silent myocardial infarction (n 21), or coronary surgery (n 34). Detection of the Intron 7 and L162V Polymorphism The intron 7 polymorphism was reported as a TaqI restriction fragment length polymorphism. 31 Human PPAR genomic sequence (Genbank AL078611) indicated that the polymorphism was situated in a TaqI fragment spanning exon 7. TaqI digestion of polymerase chain reaction (PCR) products revealed a polymorphic site, and sequencing revealed a G to C transversion at nt 2498 of intron 7 (nt of complementary strand of Genbank AL078611), 396 nt from the 3 end of intron 7. Intron 7 PCR primers were forward ACAATCACTCCTTAAATATGGTGG, reverse AAGTAGGGA- CAGACAGGACCAGTA, generating a fragment of 266bp digested by TaqI to 216bp and 50bp. PCR reactions were performed in 10 L containing 1 buffer (16 mmol/l [NH 4 ] 2 SO 4 /67 mmol/l Tris, ph 8.4/0.01% Tween 20/0.02 mmol/l each dntp), 2 mmol/l MgCl 2,8 pmol each primer, 0.1 U Taq polymerase. TaqI digestion was performed by adding 3 U of TaqI (Helena), 1.5 L restriction enzyme buffer in a volume of 5 L, and incubation for 4 hours at 65 C. L162V polymorphism genotyping has been previously described. 25 Statistical Analysis The maximum number of genotypes available for each parameter was used in analysis. Polymorphisms were checked for deviation from Hardy-Weinberg equilibrium by means of the 2 test. Allelic association was estimated by means of the Estimate Haplotype program. In LOCAT, the relation between baseline lipid levels, change in lipid levels on treatment, and PPAR genotype was examined by t test or ANOVA. Triglycerides were log-transformed. Multivariate ANOVA was used to control for baseline levels of ADS or MLD, time between the baseline and follow-up angiograms, and randomized therapy. Results are reported as unadjusted and adjusted least-squares mean SEM. In NPHS2, statistical analysis was conducted with intercooled STATA version 6.0. Body mass index (BMI), systolic blood pressure, triglycerides, and fibrinogen were log-transformed. One-way ANOVA was used to assess the effect of genotype on baseline characteristics. Survival analysis was carried out with Cox proportional hazards model, with significance assessed by the likelihood ratio test. Adjustment was performed for age, BMI, smoking status, systolic blood pressure, fibrinogen, and cholesterol. Because of the low numbers of individuals with L162V VV genotype, genotypes LV and VV were combined. Results Genotypes for the L162V and intron 7 polymorphisms were determined for 317 and 298 participants, respectively, in the LOCAT study, and for 2620 and 2684 participants, respectively, in the Second Northwick Park Heart Study. In LOCAT, allele frequencies were (95% CI, to 0.041) for the V162 allele and (95% CI, to 0.162) for the intron 7 C allele. In NPHS2, allele frequencies were (95% CI, to 0.069) for the V162 allele and (95% CI, to 0.184) for the intron 7 C allele. Frequencies of the L162V (P ) and intron 7 (P 0.01) polymorphisms were significantly lower in the LOCAT study. Polymorphisms were in Hardy-Weinberg equilibrium, with the exception of the intron 7 polymorphism in NPHS2
3 1442 Circulation March 26, 2002 TABLE 2. Estimated Haplotype Frequencies in LOCAT and NPHS2 NPHS2 L162V Intron 7 LOCAT Total Controls Cases L162 G L162 C V162 G V162 C (P 0.04), due to regional variation in allele frequency. The V162 and the intron 7 C allele were in allelic association in LOCAT ( 0.32, P 0.01) and NPHS2 ( 0.34, P ). Estimated haplotype frequencies are shown in Table 2. The association between the PPAR gene polymorphisms and plasma lipid concentrations at baseline and change in plasma lipid concentrations after gemfibrozil treatment was examined. There were no significant differences in plasma lipid concentrations in either study (Table 3) or in the change in plasma lipids in response to gemfibrozil in LOCAT (not shown) by PPAR genotype. Association between PPAR polymorphisms and progression of atherosclerosis was examined. Compared with L162 homozygotes, V162 allele carriers had significantly reduced progression of diffuse atherosclerosis in native coronary arteries (LL, mm, n 284; LV, mm, n 18; P 0.022) (Figure 1). In multivariate ANOVA, adjusting for baseline ADS, time between angiograms, and treatment, the effect remained significant (P 0.049). The effect was similar in the placebo and treated groups, with no evidence of interaction between genotype and treatment. Moreover, the LV genotype showed a protective influence against progression of focal atherosclerosis in coronary arteries ( MLD) (LL, mm, n 279, versus LV, mm, n 18; P 0.064) (Figure 1A), which was again independent of gemfibrozil treatment. Thus, carriers of the V162 allele were protected from progression of atherosclerosis. The intron 7 polymorphism also influenced the rate of progression of atherosclerosis. C allele homozygotes (n 7) TABLE 3. Figure 1. Effect of PPAR genotype on progression of atherosclerosis in LOCAT. A, L162V genotype. B, Intron 7 genotype. Carriers and homozygotes for the intron 7 C allele are combined. Values are mean SEM. Values in brackets indicate number of subjects. C, Regression model for PPAR L162V and intron 7 variants. Values are -coefficients. were combined with C allele carriers. Carriers of the C allele showed a nonsignificant trend toward greater progression of diffuse atherosclerosis ( ADS) than G allele homozygotes (GG, mm, n 213; GC CC, mm, n 70; P 0.095) (Figure 1B). Intron 7 genotype had similar effects in both placebo and treated groups. Intron 7 genotype significantly influenced progression of focal atherosclerosis ( MLD). Carriers of the C allele had a significantly greater decrease in MLD than G allele homozygotes (GG, Association Between PPAR Polymorphisms and Baseline Plasma Lipid Concentrations LL LV VV P GG GC CC P LOCAT (n 284) (n 18) (n 0) (n 213) (n 63) (n 7) Triglycerides Total cholesterol LDL HDL total NPHS2 (n 2302) (n 307) (n 11) (n 1847) (n 740) (n 97) Triglycerides Total cholesterol ApoB HDL ApoAI Values are mmol/l, mean SD.
4 Flavell et al PPAR Gene Variants and Heart Disease 1443 TABLE 4. Risk of IHD in NPHS2 by PPAR Genotype Intron 7 Genotype GG GC CC L162V Genotype LL ( ) 2.61 ( ) n 107/1675 n 43/529 n 8/49 LV VV 0.69 ( ) 0.90 ( ) 0.81 ( ) n 4/90 n 10/180 n 2/45 Cox proportional hazards model adjusted for age, BMI, cholesterol, fibrinogen, smoking, and systolic blood pressure. Numbers in parentheses are 95% CIs. Numbers of IHD events/total number in each group also are provided mm, n 209; GC CC, mm, n 69; P 0.003) (Figure 1B), an effect again observed in both placebo and treated groups. Thus intron 7 C allele carriers show increased progression of atherosclerosis. The L162V and intron 7 polymorphisms are in positive allelic association yet have opposing effects on progression of atherosclerosis. The estimated frequency of the V162-intron 7 C haplotype in LOCAT was 0.021, whereas the haplotype frequency of the V162-G haplotype was 0.006; that is, 78% of V162 alleles are on the same haplotype as the intron 7 C allele (Table 2). In a regression model, both polymorphisms showed significant effects on progression of diffuse ( ADS: constant, mm, P 0.014; V162 allele, mm, P 0.005; intron 7 C allele, mm, P 0.013) and focal ( MLD: constant, mm, P 0.001; V162 allele, mm, P 0.003; intron 7 C allele, mm, P 0.001) atherosclerosis (Figure 1C). In a multivariate regression model including baseline measures, time between angiogram, both PPAR genotypes and examining for interaction between the PPAR variants, a significant interaction was observed between PPAR genotypes for diffuse atherosclerosis ( ADS, P 0.05), with a similar trend observed for focal atherosclerosis ( MLD P 0.07). We investigated whether PPAR variants influence risk of IHD in the prospective second Northwick Park Heart Study. L162V genotype did not influence risk of events in a Cox proportional hazards model adjusted for age, BMI, cholesterol, fibrinogen, smoking, and systolic blood pressure. Carriers and homozygotes for the V162 allele combined had a hazard ratio of 0.75 (95% CI, 0.45 to 1.26, P 0.28). Intron 7 C allele homozygotes showed a nonsignificant trend for greater risk of IHD, with a hazard ratio of 1.83 (95% CI, 0.96 to 3.51, P 0.07), whereas carriers of the intron 7 C allele had a hazard ratio of 1.17 (95% CI, 0.84 to 1.63, P 0.34). When intron 7 and L162V genotype combination was examined, the V162 allele again attenuated the effect of the intron 7 C allele. Individuals homozygous for the L162 allele who were carriers of the intron 7 C allele had a 26% greater hazard ratio (1.26; 95% CI, 0.88 to 1.80, P 0.21), whereas those who were also C allele homozygotes had a 2.6-fold increased hazard ratio (2.61; 95% CI, 1.27 to 5.36, P 0.009) (Table 4). Intron 7 C allele homozygotes had a 3.2-fold greater risk of IHD if they were homozygous for the L162 allele than if they were V162 allele carriers. Haplotype frequencies were significantly different between cases and healthy individuals in NPHS2 (P 0.05), with the L-C haplotype being overrepresented in cases (0.178) compared with control subjects (0.129). Conversely, the V162 allele containing haplotypes had a lower frequency in cases than did control subjects (V-G in cases, 0.021in control subjects; V-C in cases, in control subjects) (Table 2). Kaplan-Meier survival curves are shown in Figure 2, with homozygotes for the L-C haplotype showing a significantly greater risk of IHD than combined carriers of the V162 allele, L-G haplotype homozygotes, or L-G/L-C heterozygotes. There was no interaction between PPAR genotype and smoking, BMI, or systolic blood pressure on risk of ischemic events. Discussion The present study demonstrates that variation in the PPAR gene is associated with progression of atherosclerosis and risk of IHD. Furthermore, this effect is not mediated through plasma lipid levels, suggesting that PPAR may influence the atherosclerotic process through mechanisms involving inflammation and/or oxidative stress. This further illustrates the importance of non lipid-mediated mechanisms in atherosclerosis and demonstrates that PPAR influences such mechanisms in humans. In LOCAT, both PPAR polymorphisms were associated with progression of atherosclerosis. The V162 allele was associated with reduced progression of atherosclerosis, whereas the intron 7 C allele was associated with increased progression of atherosclerosis. The V162 allele and intron 7 C allele are in strong allelic association, such that 78% of V162 alleles are found in combination with the intron 7 C allele, and the atheroprotective V162 allele strongly attenuated the Figure 2. Survival curves of IHD events by PPAR genotype in NPHS2. Adjustment was performed for age, BMI, smoking status, systolic blood pressure, fibrinogen, and cholesterol. Genotype information is presented as L162V/intron 7 genotype.
5 1444 Circulation March 26, 2002 proatherosclerotic effect of the intron 7 C allele. The PPAR intron 7 polymorphism was also associated with risk of IHD in NPHS2, and although there was no significant association with the L162V polymorphism and risk, the V162 allele again reduced the effect of the intron 7 polymorphism. The riskassociated L-C haplotype is overrepresented in subjects with IHD, whereas the V-G and V-C haplotypes are found at a lower frequency in cases than in control subjects. Surprisingly, given the well-documented effects of fibrate treatment on plasma lipid levels, the PPAR gene polymorphisms had no effect on plasma lipid concentrations in either study, confirming our previous findings. 25 It has been reported that apob and LDL cholesterol concentrations are higher in carriers of the V162 allele, 32,33 though we did not observe such a finding, possibly because of differences in the subject selection criteria. In the LOCAT study, a similar effect of PPAR genotype on progression of atherosclerosis was observed in both placebo and treated groups, suggesting that these variants in the PPAR gene do not dramatically influence response to fibrate treatment, as previously observed. 25,34 The absence of an association between PPAR polymorphisms and plasma lipid levels suggests that the effect of the PPAR polymorphisms on IHD is not plasma lipid mediated unless subtle alterations occur in plasma lipid profiles. Additionally, the risk of IHD was unchanged when plasma cholesterol levels were included in the Cox proportional hazards model. PPAR is also expressed in vessel wall cell types and regulates the expression of genes that influence proatherosclerotic processes in these cells. Inflammation plays a major role in both the initiation and progression of atherosclerosis, 1 and PPAR activation has antiinflammatory actions. 35 PPAR also influences oxidative stress. 19,23 Thus, PPAR polymorphisms may affect progression of atherosclerosis through inflammatory and/or oxidative stress mechanisms. The mechanism by which the intron 7 variant influences the atherosclerotic process remains unclear. PPAR -V162 has higher transcriptional activation in vitro. 25,26 No other common missense variants have been identified in the PPAR gene coding region. 25,26,33 Given the opposing effects of the V162 allele and the intron 7 C allele and the beneficial effects of stimulation of PPAR activity with fibrates, we hypothesize that the intron 7 C allele is associated with lower levels of PPAR. It is unlikely that the intron 7 variant is itself functional, due to its position in an intron. However, we suggest that it is in allelic association with a functional variant in a promoter or enhancer element of the PPAR gene that results in reduced PPAR gene expression. Surprisingly, PPAR knockout mice crossed with the apoe knockout mouse on an atherogenic diet show reduced aortic atherosclerosis compared with apoe knockout control mice. 36 Thus, PPAR affects factors that contribute to the atherosclerotic process, and common variation in the human PPAR gene influences these factors. These data demonstrate the important role of PPAR in human atherogenesis and provide genetic evidence that PPAR has antiatherosclerotic effects in humans in vivo and so influences risk of IHD. Acknowledgments Drs Jamshidi, Humphries, and Torra are supported by British Heart Foundation grants FS/98058 and RG/ Dr Talmud is supported by a European Community grant (ERBFMBICT983214), and Bart Staels is supported by grants of the Institut Pasteur de Lille and INSERM. The LOCAT study was supported by Parke-Davis, the Finnish Foundation for Cardiovascular Research, the Aarne Koskelo Foundation, and the Finnish Society of Angiology. NPHS2 was supported by the Medical Research Council, the US National Institutes of Health (grant NHLBI 33014) and Du Pont Pharma. References 1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340: Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347: Krey G, Braissant O, L Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997;11: Fruchart J-C, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999; 10: Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mrnas of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 1997;46: Inoue I, Shino K, Noji S, et al. Expression of peroxisome proliferatoractivated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun. 1998;246: Staels B, Koenig W, Habib A, et al. Activation of human aortic smoothmuscle cells is inhibited by PPAR but not by PPAR activators. Nature. 1998;393: Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273: Chinetti G, Gbaguidi FG, Griglio S, et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator activated receptors. Circulation. 2000;101: Zhu L, Bisgaier CL, Aviram M, et al. 9-Cis retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells. Arterioscler Thromb Vasc Biol. 1999;19: Delerive P, Martin Nizard F, Chinetti G, et al. Peroxisome proliferatoractivated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85: Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999;19: Marx N, Sukhova GK, Collins T, et al. PPAR activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99: Shu H, Wong B, Zhou G, et al. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun. 2000; 267: Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7: Neve BP, Corseaux D, Chinetti G, et al. PPAR agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001;103: Marx N, Mackman N, Schonbeck U, et al. PPAR activators inhibit tissue factor expression and activity in human monocytes. Circulation. 2001;103: Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274:
6 Flavell et al PPAR Gene Variants and Heart Disease Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factorkappab signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 1998;273: Madej A, Okopien B, Kowalski J, et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther. 1998;36: Devchand PR, Keller H, Peters JM, et al. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 1996;384: Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999;85: Inoue I, Noji S, Awata T, et al. Bezafibrate has an antioxidant effect: peroxisome proliferator- activated receptor alpha is associated with Cu2, Zn2 -superoxide dismutase in the liver. Life Sci. 1998;63: Watts GF, Dimmitt SB. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol. 1999;10: Flavell DM, Pineda Torra I, Jamshidi Y, et al. Variation in the PPAR gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia. 2000;43: Sapone A, Peters JM, Sakai S, et al. The human peroxisome proliferatoractivated receptor gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics. 2000;10: Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation. 1997;96: Miller GJ, Bauer KA, Barzegar S, et al. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost. 1996;75: Syvanne M, Nieminen MS, Frick MH, et al. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation. 1998;98: Syvanne M, Nieminen MS, Frick MH. Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery. A validation study. Int J Card Imaging. 1994; 10: Sher T, Yi HF, McBride OW, et al. cdna cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32: Vohl M-C, Lepage P, Gaudet D, et al. Molecular scanning of the human PPAR gene: association of the L162V mutation with hyperapobetalipoproteinemia. J Lipid Res. 2000;41: Lacquemant C, Lepretre F, Pineda T, et al. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab. 2000;26: Jamshidi Y, Flavell DM, Hawe E, et al. Genetic determinants of the response to bezafibrate treatment in the Lower Extremity Arterial Disease Event Reduction (LEADER) trial. Atherosclerosis. In press. 35. Delerive P, Fruchart C, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol.;2001;169: Tordjman K, Bernal-Mizrachi C, Zemany L, et al. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoe-null mice. J Clin Invest. 2001;107:
Progression of Atherosclerosis Is Associated With Variation in the 1 -Antitrypsin Gene
Progression of Atherosclerosis Is Associated With Variation in the 1 -Antitrypsin Gene Philippa J. Talmud, Steve Martin, George Steiner, David M. Flavell, David B. Whitehouse, Sylvia Nagl, Richard Jackson,
More informationProgression of Atherosclerosis Is Associated With Variation in the 1 -Antitrypsin Gene
Progression of Atherosclerosis Is Associated With Variation in the 1 -Antitrypsin Gene Philippa J. Talmud, Steve Martin, George Steiner, David M. Flavell, David B. Whitehouse, Sylvia Nagl, Richard Jackson,
More informationEFFECTS OF PPARγ LIGANDS ON ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE
EFFECTS OF PPARγ LIGANDS ON ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE C. Fiévet and B. Staels, Institut Pasteur de Lille, Département d Athérosclérose, Lille, F- 59019 France, Inserm, U545, Lille, F-59019
More informationAPOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study
APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study Philippa J. Talmud, 1, * Steve Martin,* Marja-Riitta Taskinen, M. Heikki
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationAPOA5 GENE VARIANTS, LIPOPROTEIN PARTICLE DISTRIBUTION AND PROGRESSION OF CORONARY HEART DISEASE: RESULTS FROM THE LOCAT STUDY.
APOA5 GENE VARIANTS, LIPOPROTEIN PARTICLE DISTRIBUTION AND PROGRESSION OF CORONARY HEART DISEASE: RESULTS FROM THE LOCAT STUDY. Philippa J Talmud 1, Steve Martin 1, Marja-Riitta Taskinen 2, M. Heikki Frick
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationFibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit
Focus on CME at the University of Alberta Spotlight on By T. K. Lee, MSc (Exp. Medicine), MB, BS, MRCP(UK), ABIM, FRCPC As presented at the Drug Update & Practical Therapeutics Course, November 8, 2002.
More informationand Restenosis Yangsoo Jang, MD, PhD. Yonsei University College of Medicine
PPAR- Agonist and In-Stent Restenosis Yangsoo Jang, MD, PhD. Yonsei University College of Medicine Peroxisome Proliferator- activated Receptors (PPAR) Lipid-activated transcription factors : => regulating
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationPPAR history of research
PPAR Rubens, 1640 PPAR history of research number of publications 3000 2000 1000 0 till now: : 16 296 publications 1985 1990 1995 2000 2005 year liver, brown adipocytes, kidney, heart, skeletal muscles,
More informationORIGINAL INVESTIGATION. Gemfibrozil in the Treatment of Dyslipidemia. An 18-Year Mortality Follow-up of the Helsinki Heart Study
ORIGINAL INVESTIGATION Gemfibrozil in the Treatment of Dyslipidemia An 18-Year Mortality Follow-up of the Helsinki Heart Study Leena Tenkanen, PhD; Matti Mänttäri, MD; Petri T. Kovanen, MD; Hanna Virkkunen,
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationPPAR genomics and pharmacogenomics: Implications for cardiovascular disease
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2008 PPAR genomics and pharmacogenomics: Implications for cardiovascular disease Sharon Cresci Washington University
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationEicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different?
Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different? Trevor A Mori, Ph.D., Professor, School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth,
More informationRole of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal
More informationCentral role of apociii
University of Copenhagen & Copenhagen University Hospital Central role of apociii Anne Tybjærg-Hansen MD DMSc Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen,
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More information902 Biomed Environ Sci, 2014; 27(11):
902 Biomed Environ Sci, 2014; 27(11): 902-906 Letter to the Editor Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationLIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 : EFFECTS OF LOW DENSITY LIPOPROTEIN APHERESIS
LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 : EFFECTS OF LOW DENSITY LIPOPROTEIN APHERESIS Patrick M. Moriarty, M.D., FACP, Director, Atherosclerosis and LDL-Apheresis Center, University of Kansas Medical
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationCho et al., 2009 Journal of Cardiology (2009), 54:
Endothelial Dysfunction, Increased Carotid Artery Intima-media Thickness and Pulse Wave Velocity, and Increased Level of Inflammatory Markers are Associated with Variant Angina Cho et al., 2009 Journal
More informationLipid/Lipoprotein Structure and Metabolism (Overview)
Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL A Meta-analysis of LDL-C, non-hdl-c, and apob as markers of cardiovascular risk. Slide # Contents 2 Table A1. List of candidate reports 8 Table A2. List of covariates/model adjustments
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationNovel Markers of Arterial Dysfunction
혈관연구회창립심포지움, 3 월 3 일, 2005 Novel Markers of Arterial Dysfunction Kwang Kon Koh, MD, FACC, FAHA Cardiology Gachon Medical School Incheon, Korea Atherosclerosis: A progressive process PHASE I: Initiation
More informationCardiovascular Division, Brigham and Women s Hospital, Harvard Medical School
Low Endothelial Shear Stress Upregulates Atherogenic and Inflammatory Genes Extremely Early in the Natural History of Coronary Artery Disease in Diabetic Hyperlipidemic Juvenile Swine Michail I. Papafaklis,
More informationPATIENTS AND METHODS:
BACKGROUND: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by erosive synovitis that involves peripheral joints and implicates an important influence in the quality
More informationCardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009
Cardiovascular disease, studies at the cellular and molecular level Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009 Content Introduction The number 1 killer in America Some statistics
More informationThe aorta is an integral part of the cardiovascular system and should not be considered as just a conduit for blood supply from the heart to the
The aorta is an integral part of the cardiovascular system and should not be considered as just a conduit for blood supply from the heart to the limbs and major organs. A range of important pathologies
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationAssociation between interleukin-17a polymorphism and coronary artery disease susceptibility in the Chinese Han population
Association between interleukin-17a polymorphism and coronary artery disease susceptibility in the Chinese Han population G.B. Su, X.L. Guo, X.C. Liu, Q.T. Cui and C.Y. Zhou Department of Cardiothoracic
More informationPotential mechanisms for the resolution of atherosclerosis by conjugated linoleic acid (CLA)
HRB IMDA Oct HRB 2010 IMDA Seminar 28 th Oct 2010 Potential mechanisms for the resolution of atherosclerosis by conjugated linoleic acid (CLA) Dr. Orina Belton, School of Biomolecular and Biomedical Science,
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationBy: Dr Mehrnoosh Shanaki
Resveratrol could partly improve the crosstalk between canonical β-catenin/wnt and FOXO pathways in coronary artery disease patients with metabolic syndrome: A case control study By: Dr Mehrnoosh Shanaki
More informationRegence. Medical Policy Manual. Date of Origin: May Topic: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment
Regence Medical Policy Manual Topic: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment Date of Origin: May 2013 Section: Genetic Testing Last Reviewed Date: June 2013
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationCardiovascular disease and diabetes Vascular harmony
Cardiovascular disease and diabetes 2018 Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationTaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia
(2005) 13, 877 882 & 2005 Nature Publishing Group All rights reserved 1018-4813/05 $30.00 www.nature.com/ejhg ARTICLE TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease
More informationTissue factor (TF) is an integral membrane protein, which
PPAR Activators Inhibit Tissue Factor Expression and Activity in Human Monocytes Nikolaus Marx, MD; Nigel Mackman, PhD; Uwe Schönbeck, PhD; Nurcan Yilmaz, MS; Vinzenz Hombach, MD; Peter Libby, MD; Jorge
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationGemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation
Diabetologia (2006) 49: 766 774 DOI 10.1007/s00125-005-0102-6 ARTICLE A. C. Calkin. M. E. Cooper. K. A. Jandeleit-Dahm. T. J. Allen Gemfibrozil decreases atherosclerosis in experimental diabetes in association
More informationHigh density lipoprotein metabolism
High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC
More informationCETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia
CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationCardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010
Cardiovascular disease, studies at the cellular and molecular level Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010 Content Introduction The number 1 killer in America Some statistics
More informationIncreased Expression of Peroxisome Proliferator-Activated Receptor- and - in Blood Vessels of Spontaneously Hypertensive Rats
Increased Expression of Peroxisome Proliferator-Activated Receptor- and - in Blood Vessels of Spontaneously Hypertensive Rats Quy N. Diep, Ernesto L. Schiffrin Abstract Peroxisome proliferator-activated
More informationA total of 2,822 Mexican dyslipidemic cases and controls were recruited at INCMNSZ in
Supplemental Material The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL-receptor degradation in humans by Daphna Weissglas-Volkov et al. Supplementary Methods Mexican
More informationThe Relationship between Dietary Fatty Acids and Inflammatory Genes on the Obese Phenotype and Serum Lipids
Nutrients 2013, 5, 1672-1705; doi:10.3390/nu5051672 Review OPEN ACCESS nutrients ISSN 2072-6643 www.mdpi.com/journal/nutrients The Relationship between Dietary Fatty Acids and Inflammatory Genes on the
More informationRole of inflammatory parameters in the susceptibility of cerebral thrombosis
Role of inflammatory parameters in the susceptibility of cerebral thrombosis X.F. Qi 1, T.J. Feng 2, P. Yang 1, H.Y. Feng 3, P. Zhang 2, L.Y. Kong 1, D.L. Liang 1, P.F. Li 4, W. Na 5, Y.W. Li 5 and Y.
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationSecond Generation of Calcium Antagonists
Winifred G. Nayler Second Generation of Calcium Antagonists With 81 Figures and 63 Tables Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong Barcelona Budapest Contents Foreword Chapter
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationTaylor Yohe. Project Advisor: Dr. Martha A. Belury. Department of Human Nutrition at the Ohio State University
Atherosclerosis Development and the Inflammatory Response of Hepatocytes to Sesame Oil Supplementation Taylor Yohe Project Advisor: Dr. Martha A. Belury Department of Human Nutrition at the Ohio State
More informationLIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE
LIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE Sebastiano Calandra Dipartimento di Scienze Biomediche Università di Modena e Reggio Emilia Incidence Rate/1000 200-150 - 100-50 - Women 0 Men
More informationPathology of Coronary Artery Disease
Pathology of Coronary Artery Disease Seth J. Kligerman, MD Pathology of Coronary Artery Disease Seth Kligerman, MD Assistant Professor Medical Director of MRI University of Maryland Department of Radiology
More informationPresented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer
Presented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer Patients Randomized by Country 187 UK n=187 Norway n=425 Finland
More informationSummary and concluding remarks
Summary and concluding remarks This thesis is focused on the role and interaction of different cholesterol and phospholipid transporters. Cholesterol homeostasis is accomplished via a tightly regulated
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More information10/17/16. Assessing cardiovascular risk through use of inflammation testing
Assessing cardiovascular risk through use of inflammation testing Anthony L. Lyssy, DO Medical Director and Managing Partner Diamond Physicians Dallas, TX Response to Injury Hypothesis Injury Response
More informationTitle for Paragraph Format Slide
Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationInfluences of Matrix Metalloproteinase-3 Gene Variation on Extent of Coronary Atherosclerosis and Risk of Myocardial Infarction
Journal of the American College of Cardiology Vol. 41, No. 12, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00482-0
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationAssociation of plasma uric acid with ischemic heart disease and blood pressure:
Association of plasma uric acid with ischemic heart disease and blood pressure: Mendelian randomization analysis of two large cohorts. Tom M Palmer, Børge G Nordestgaard, DSc; Marianne Benn, Anne Tybjærg-Hansen,
More informationAssociation of liver X receptor α (LXRα) gene polymorphism and ischemic stroke
Association of liver X receptor α (LXRα) gene polymorphism and ischemic stroke H.X. Wang 1, K. Zhang 2, L. Zhao 1, J.W. Tang 1, L.Y. Gao 1 and Z.P. Wei 1 1 Department of Neurology, The Affiliated Fourth
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More informationLp(a) Ready for prime time? E Stroes AMC
Lp(a) Ready for prime time? E Stroes AMC Case Male, 45 years old Hypertension: DM: Smoking: Dyslipidemia: Fam history: brother MI (55yr) Lipoprotein(a): 1240 mg/l!!! Lipoprotein(a) = LDL + apo(a) tail
More informationGlossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationThe changes of serum BDNF, blood lipid and PCI in the elderly patients with coronary heart disease complicated with diabetes mellitus
184 Journal of Hainan Medical University 2016; 22(16): 184-188 Journal of Hainan Medical University http://www.hnykdxxb.com/ The changes of serum BDNF, blood lipid and PCI in the elderly patients with
More informationATHEROSCLEROTIC cardiovascular complications are the leading cause of. Diabetes Mellitus Has an Additional Effect on Coronary Artery Disease
Diabetes Mellitus Has an Additional Effect on Coronary Artery Disease To Decrease Plasma Adiponectin Levels Kuei-Chuan CHAN, 1 MD, Hsi-Hsien CHOU, 1 PhD, Der-Jinn WU, 1 PhD, Yi-Liang WU, 1 MD, and Chien-Ning
More informationChild born in year /3 will die before parents in US (diabetes)
Child born in year 2000-1/3 will die before parents in US (diabetes) ATP III identified 6 components of the metabolic syndrome that relate to CVD 1. Abdominal obesity 2. Atherogenic dyslipidemia (elevated
More informationEmmanouil S. Brilakis 1{, Joseph P. McConnell 2, Ryan J. Lennon 3, Ahmad A. Elesber 1, Jeffrey G. Meyer 2, and Peter B. Berger 4 * Introduction
European Heart Journal (2005) 26, 137 144 doi:10.1093/eurheartj/ehi010 Clinical research Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic
More informationAnnals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More informationKEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers
CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes
More informationInflammation: Novel Target for Cardiovascular Risk Reduction
Inflammation: Novel Target for Cardiovascular Risk Reduction Andrew Zalewski, M.D. Thomas Jefferson University, Philadelphia GlaxoSmithKline, Philadelphia Why inflammation? Population-based studies: low
More informationMechanisms of Action for Arsenic in Cardiovascular Toxicity and Implications for Risk Assessment
Mechanisms of Action for Arsenic in Cardiovascular Toxicity and Implications for Risk Assessment Mandeep Sidhu, MD, MBA, FACC Assistant Professor of Medicine Division of Cardiology Albany Medical College
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationSupplementary Table I - Primers used for real-time quantitative PCR and RT-PCR
Supplement Supplementary Table I - Primers used for real-time quantitative PCR and RT-PCR Gene Forward Primer (5-3 ) Reverse primer (5-3 ) Reference Human ST2 CTTGATTGATAAACAGAATG CTGATCCAGATACTGTTGAA
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationAcute coronary syndrome. Dr LM Murray Chemical Pathology Block SA
Acute coronary syndrome Dr LM Murray Chemical Pathology Block SA13-2014 Acute myocardial infarction (MI) MI is still the leading cause of death in many countries It is characterized by severe chest pain,
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More information